Although RNA polymerase II is the core enzyme that carries out transcription, it requires a large number of accessory proteins and protein complexes to regulate its activity. One of the most important of these complexes is Mediator, a group of 20-25 protein components that is highly conserved from Saccharomyces cerevisiae through to humans. [1] [2] [3] [4] [5] [6] The yeast Mediator is subdivided into three portions: a head region that contacts RNA polymerase II, a middle region, and a tail (Figure 1 ). [7] While the functions of most of the Mediator subunits are unknown, a preponderance of evidence suggests that Mediator integrates information from DNA-bound transcriptional activators and repressors to RNA polymerase II, informing it as to the extent and level of up-regulation required. [8] It has been difficult to precisely assign the function and role of the Mediator complex and its subunits both because most are important for different subsets of genes and because all participate in multiple protein-protein interactions. Deleterious and/or pleiotropic effects are often observed upon either deletion or mutation of these proteins. Molecules that inhibit particular protein-protein interactions within this complex would thus be invaluable for parsing the role(s) of these proteins in transcriptional regulation. Here, we report the first inhibitor of a protein-protein interaction within the Mediator complex, an eight-residue peptide that prevents the association of Med15A C H T U N G T R E N N U N G (Gal11) and Med14-A C H T U N G T R E N N U N G (Rgr1) at low micromolar concentrations. This peptide thus serves as a key starting point for the development of a new class of artificial transcriptional regulators.
Although the locations of individual proteins within each Mediator subcomplex are not known with high precision, several lines of evidence suggest that Med14A C H T U N G T R E N N U N G (Rgr1) (middle module) and Med15A C H T U N G T R E N N U N G (Gal11) (tail module) reside at the interface between the tail and middle portions. [1, 9] Genetic studies indicate that Med14A C H T U N G T R E N N U N G (Rgr1) and Med15A C H T U N G T R E N N U N G (Gal11) affect overlapping but distinct sets of genes. [10] Med14A C H T U N G T R E N N U N G (Rgr1) (also known as ARC/ DRIP150, TRAP170, or CRSP150 in humans) is an essential protein and has been identified in multiple genetic screens in S. cerevisiae as both a positive and negative regulator of transcription. [9, 10] Mutations in Med14A C H T U N G T R E N N U N G (Rgr1) diminish Ty, GAL, and MATa gene expression. [9] In addition, Med14A C H T U N G T R E N N U N G (Rgr1) is required for the repression of the MAL structural genes and RME1-mediated repression of meiosis in haploid yeast cells under starvation conditions. [11, 12] However, little is known about its specific function or interaction partners.
Med15A C H T U N G T R E N N U N G (Gal11) is commonly identified as a target of transcriptional activators, interacting in vitro with more than 10 activators; studies in S. cerevisiae support the functional relevance of these interactions. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Although a direct homologue of Med15A C H T U N G T R E N N U N G (Gal11) has not been identified in metazoans, the amino terminal domain with which many activators interact is proposed to be a KIX domain, found in a number of metazoan coactivators (CBP/p300 and ARC105, for example), although this domain can be removed without a significant impact on function. [1, 23] 
is not an essential protein, as deletion is not lethal but rather induces a slowgrowth phenotype. [24] Although a direct interaction has not been demonstrated, Med14A C H T U N G T R E N N U N G (Rgr1) appears necessary for the A C H T U N G T R E N N U N G association of Med15A C H T U N G T R E N N U N G (Gal11) with Mediator. Mediator complex that contains truncated versions of Med14A C H T U N G T R E N N U N G (Rgr1) does not contain Med15A C H T U N G T R E N N U N G (Gal11), for example. [9] These studies thus suggest that ligands that interact with either Med15A C H T U N G T R E N N U N G (Gal11) or Med14-A C H T U N G T R E N N U N G (Rgr1) could directly or indirectly inhibit the association of these proteins.
In an earlier study we carried out a screen against the middle portion of Med15A C H T U N G T R E N N U N G (Gal11) (residues 186-619) by using two 8-residue peptide libraries of general composition Ala- 4 -(Pro/Leu)-Ser-Glu and identified 37 ligands for this protein (see ref. [28] for a complete list). To identify ligands that might target binding surfaces that Med15A C H T U N G T R E N N U N G (Gal11) uses for interactions with other Mediator proteins, we carried out a BLAST search against these short peptides to identify sequences that had overlap with potential binding partners of Med15A C H T U N G T R E N N U N G (Gal11). For this purpose we used the 2.1.3 BLAST protocol specifically developed for short sequences and focused upon hits for which there was some genetic and/or biochemical evidence of an interaction. [25] Peptide 32 (Ala-Tyr-Phe-Glu-Val-Pro-Ser-Glu) exhibited significant (E = 75) overlap with residues 277-283 (Tyr-Phe-Thr-Val-Pro-Asn-Glu) in Med14A C H T U N G T R E N N U N G (Rgr1) (Figure 1 B) . These residues reside in the N-terminal portion of Rgr1, which is essential for viability and has the highest sequence similarity to homologues in higher eukaryotes. [1] This result was suggestive both of a direct interaction between Med15A C H T U N G T R E N N U N G (Gal11) and Med14-A C H T U N G T R E N N U N G (Rgr1), and of a mechanism by which association of the two proteins could be inhibited.
To investigate this hypothesis, we first identified conditions under which the association of Med14A C H T U N G T R E N N U N G (Rgr1) and Med15A C H T U N G T R E N N U N G (Gal11) could be observed. Although several fragments of Med15-A C H T U N G T R E N N U N G (Gal11) have been bacterially over-expressed and studied, constructs for Med14A C H T U N G T R E N N U N G (Rgr1) (123 kDa) bacterial expression have not been reported. We thus elected to examine the interaction of the entire protein with Med15A C H T U N G T R E N N U N G (Gal11), using a protein Atagged variant for isolation and detection. Homologous recombination in S. cerevisiae was used to tag Med14A C H T U N G T R E N N U N G (Rgr1) for isolation and detection purposes by using standard protocols. [26, 27] Protein A incorporation was confirmed by PCR, and expression of the tagged protein was verified by analysis of yeast extracts by SDS-PAGE followed by Western blotting with the PAP antibody to detect the protein A-tagged Med14A With conditions for observing the association of Med14-A C H T U N G T R E N N U N G (Rgr1) and Med15A C H T U N G T R E N N U N G (Gal11) in hand, we then tested whether or not peptide 32 could inhibit the formation of this complex. For this purpose, peptide 32 was synthesized by using standard solid-phase synthesis techniques, and the crude material thus obtained was purified to homogeneity by reversed-phase HPLC. The identity of the isolated peptide was verified by electrospray mass spectrometry. A portion of peptide 32 was A C H T U N G T R E N N U N G labeled at the amino terminus with fluorescein, purified by A C H T U N G T R E N N U N G reversed-phase HPLC, and used in a fluorescence-polarization A C H T U N G T R E N N U N G experiment to measure the affinity of peptide 32 for Med15-A C H T U N G T R E N N U N G (Gal11). Peptide 32 interacts with Med15A C H T U N G T R E N N U N G (Gal11) with a K D of 2.4 mm, similar to that of other Med15A C H T U N G T R E N N U N G (Gal11) peptide ligands isolated from binding screens. [28] In addition to peptide 32, a scrambled version of this sequence (scr32: Tyr-Glu-Val-Phe-AlaSer-Pro-Glu) was synthesized for use as a negative control.
Yeast extracts containing protein A-tagged Med14A C H T U N G T R E N N U N G (Rgr1) were combined with 10 mg of recombinant GST-Med15A C H T U N G T R E N N U N G (Gal11) (186-619) and glutathione agarose beads. Also included in the mixture was peptide 32 at concentrations ranging from 1 mm to 5 mm, and each reaction mixture was incubated with rotation for 2 h at 4 8C. The beads were washed several times with extract buffer, and the bound protein complex was separated by SDS-PAGE and detected by Western blot analysis. As shown in Figure www.chembiochem.org signals for a range of genes, at micromolar concentrations. Importantly, there is some level of specificity associated with this inhibition. The experiments were carried out with yeast lysates, such that there was a high number of potential binding partners within the assay mixture. In addition, when the sequence of the peptide was scrambled, no discernable inhibition occurred under identical conditions. As the first reported inhibitor of a Mediator protein-protein interaction, peptide 32 will be a useful mechanistic tool on a number of fronts. Perhaps most promising, peptide 32 can be used as the starting point for identifying nonpeptidic inhibitors through competitive binding assays, and such molecules could have enhanced utility in cell-based experiments. Finally, other mediator components can be submitted to similar peptide/small-molecule screens to identify not only potential protein partners and inhibitors of contacts between Mediator components, but, depending on the target, novel artificial transcriptional activation domains. Future peptide/small-molecule inhibitors of Mediator interactions will be useful for dissecting the roles of individual subunits and mediator modules in conveying signals from transcriptional regulators to RNA polymerase II and in preinitiation complex (PIC) assembly.
Experimental Section
Isolation of protein A-tagged Med14A C H T U N G T R E N N U N G (Rgr1): To C-terminally protein A-tagged Med14A C H T U N G T R E N N U N G (Rgr1) under its natural promoter, primers containing 40 base pairs homologous to the C terminus of Med14-A C H T U N G T R E N N U N G (Rgr1) and the 3' untranslated region of Med14A C H T U N G T R E N N U N G (Rgr1) were designed to PCR and then clone the protein A tag and Kan marker from pFA6a-KanMX6 with protein A. [26, 27] The forward primer was 5'-CATAATATCCTCAAAGTGGACTCGAACTCAAGTTCATCTCGGATCCC-A C H T U N G T R E N N U N G CA C H T U N G T R E N N U N G GGGTTAATTAA-3'. The reverse primer was 5'-CTCCTAAGGGATAGT-A C H T U N G T R E N N U N G AA C H T U N G T R E N N U N G GCGCCGGTGACATTTTATTCGCTGAATTCGAGCTCGTTTAAAC-3'. PCR reactions contained dNTPs (200 mm), the forward and reverse primer (2 mm), and pFA6a-KanMX6 (100 ng; 50 mL total volume). The amplification profile was one cycle for 3 min at 95 8C followed by 30 cycles of 15 s at 95 8C, 1 min at 50 8C, and 2 min at 72 8C. The final extension step was 7 min at 72 8C. The correct PCR fragment was verified by gel electrophoresis. Several PCR reaction mixtures were combined and transformed into S. cerevisiae (BJ2168, genotype: MATalpha,ura3-52,leu2,gal2,prb1-1122,1pep4-3,prc1-407) by using the lithium acetate method. Integration of the protein A tag at the C terminus of Med14A C H T U N G T R E N N U N G (Rgr1) was verified by Western blot and PCR analysis of the transformed yeast colonies that survived on SC G418 (500 mg mL À1 ) plates. Yeast containing the integrated protein A tag at the C terminus of Med14A C H T U N G T R E N N U N G (Rgr1) were used to inoculate an overnight culture (50 mL), which was subsequently diluted 500-fold to inoculate YPD media (1 L). The culture was grown to an OD of 3 before the cells were centrifuged at 5000 rpm for 5 min. The pellets were stored at À80 8C until needed. (http://www.fhcrc.org/ science/labs/hahn/methods/methods_index.html) In order to lyse, the cells the pellet was washed with sterilized ddH 2 O (50 mL) then extract buffer (200 mm Tris-HCl pH 8.0, 150 mm ammonium sulfate, 10 % glycerol, 1 mm EDTA, 2 mm DTT, Roche protease inhibitor tablet; 25 mL) both prechilled to 4 8C. The cells were resuspended in extract buffer and lysed by using glass beads at 4 8C with a 1 min vortex, 1 min cooling cycle, repeated 5 times. The glass bead-cell lysate mixture was centrifuged for 3 min at 14 000 rpm and 4 8C, and the supernatant was centrifuged again for 30 min at 14 000 rpm and 4 8C. The supernatant was concentrated in a spin filter, and aliquots (1 mL) were used in pull-down experiments.
GST-Med15A C H T U N G T R E N N U N G (Gal11)A C H T U N G T R E N N U N G (186-619) was over-expressed in Rosetta2A C H T U N G T R E N N U N G (DE3) pLysS E. coli cells and isolated as previously described. [28] Competitive inhibition experiments: For the peptide competition experiments, GST-Med15 (186-619) (50 mL, 20 mm) was added with yeast extracts (1 mL) and a range of concentrations of peptide 32 or scrambled peptide 32 (scr32) to glutathione beads (50 mL) and mixed end on end at 4 8C for 2 h. The beads were washed with A C H T U N G T R E N N U N G extract buffer (3 ) , and the bound protein was eluted by boiling in NUPAGE LDS 4 loading buffer. The supernatant (15 mL) was loaded and separated by SDS-PAGE and detected by Western blot by using chemiluminescence.
